The European Committee for Medicinal Products for Human Use (CHMP) has issued positive opinions on three promising new drug candidates, signaling potential advancements in the treatment of complex and often debilitating diseases. These recommendations cover therapies developed by global pharmaceutical giants Novartis, Arrowhead Pharmaceuticals, and Sanofi, targeting autoimmune disorders, rare genetic conditions, and muscle-wasting diseases. The CHMP’s endorsements mark a critical step forward in making these innovative treatments available to patients across the European continent.
Sanofi’s Cenrifki (tolebrutinib) Receives Positive Opinion for Multiple Sclerosis
Sanofi has announced a significant milestone with the CHMP’s positive opinion on its investigational therapy, Cenrifki (tolebrutinib), for the treatment of non-relapsing secondary progressive multiple sclerosis (nrSPMS). This recommendation comes at a pivotal moment, following a setback in the United States where the Food and Drug Administration (FDA) declined to approve the drug, citing concerns regarding potential liver injury risks.
Cenrifki, a Bruton’s tyrosine kinase (BTK) inhibitor, demonstrated its efficacy in the Phase III HERCULES trial (NCT04411641). The trial results, which formed the basis of the CHMP’s positive assessment, revealed that Cenrifki significantly delayed the time to six-month confirmed disability progression by 31% compared to a placebo. This finding suggests a meaningful benefit for patients suffering from the relentless progression of MS, a chronic autoimmune disease that affects the central nervous system.
The CHMP’s decision to recommend Cenrifki for approval in Europe underscores a different regulatory perspective compared to the US. While the concerns about liver injury remain a subject of careful consideration, the European regulatory body has weighed the demonstrated clinical benefits against potential risks. Sanofi anticipates a final decision from the European Medicines Agency (EMA) regarding the drug’s market authorization in the coming months.
The landscape of MS treatment is evolving rapidly, with BTK inhibitors emerging as a significant class of therapeutics. However, safety profiles are under intense scrutiny. Cenrifki’s journey is unfolding against a backdrop where other BTK inhibitors, such as Roche’s fenebrutinib, are also facing similar safety challenges in their development for multiple sclerosis. Experts in the field, previously interviewed by Clinical Trials Arena, a sister publication of Pharmaceutical Technology, have highlighted the substantial uptake potential for BTK inhibitors in MS management. Nonetheless, they emphasize the crucial need for healthcare providers to meticulously monitor patients’ liver enzyme levels to mitigate any potential adverse events.
The development of tolebrutinib by Sanofi is part of a broader effort to address the unmet needs in progressive forms of MS, which have historically seen fewer therapeutic options compared to relapsing forms of the disease. The drug’s mechanism of action, targeting B cells and microglia within the central nervous system, aims to reduce inflammation and neurodegeneration, key drivers of disability progression in MS.
Arrowhead Pharmaceuticals’ Redemplo (plozasiran) Poised for European Market Entry
Arrowhead Pharmaceuticals is also celebrating a positive CHMP opinion for its innovative therapy, Redemplo (plozasiran), a treatment for a rare genetic disorder affecting fat metabolism. While Redemplo has already secured approval and launched in the United States for patients diagnosed with familial chylomicronemia syndrome (FCS), a condition characterized by the body’s inability to break down certain fats, its European debut hinges on this CHMP recommendation.
FCS is a severe and life-threatening condition where high levels of triglycerides in the blood can lead to recurrent episodes of acute pancreatitis. Redemplo, an RNA interference (RNAi) therapeutic, targets the APO-CIII gene, a key regulator of triglyceride levels. By silencing this gene, Redemplo aims to dramatically reduce triglyceride levels, thereby preventing the severe complications associated with FCS.
The CHMP’s positive opinion is based on the robust data from the Phase III PALISADE study (NCT05089084). This pivotal trial demonstrated Redemplo’s remarkable efficacy, achieving a median reduction of 80% in patient triglyceride levels from baseline. This significant reduction translated into a substantial decrease in the incidence of acute pancreatitis events when compared to placebo. Arrowhead anticipates an EMA decision on Redemplo’s marketing authorization in the second quarter of 2026.
If approved in Europe, Redemplo would mark a significant therapeutic advancement, potentially becoming the first and only small interfering RNA (siRNA) therapy available for FCS in the region. This would position Arrowhead to challenge the current European market dominance held by Ionis Pharmaceuticals, whose therapies Tryngolza (olezarsen) and the co-developed Waylivra (volanesorsen) also address this rare condition.
Industry analysts at GlobalData, the parent company of Pharmaceutical Technology, forecast a bright commercial future for Redemplo. Their consensus analysis predicts that the drug could generate $1 billion in sales by 2032, surpassing the projected revenues of both Waylivra and Tryngolza. This optimistic outlook reflects the significant unmet need in FCS and the potential of Redemplo to offer a superior therapeutic option.
The development of RNAi therapies for rare genetic disorders represents a significant frontier in precision medicine. Arrowhead’s focus on targeting specific genes involved in metabolic pathways offers a novel approach to treating conditions that have historically been challenging to manage. The PALISADE study’s success underscores the potential of this platform to deliver profound clinical benefits.
Novartis’ Itvisma (onasemnogene abeparvovec) Gains CHMP Support for Spinal Muscular Atrophy
Novartis is also set to expand its presence in the European market with the CHMP’s positive opinion on Itvisma (onasemnogene abeparvovec), a groundbreaking gene therapy for spinal muscular atrophy (SMA). Itvisma, which gained FDA approval and launched in the US in November 2025, is designed to treat SMA, a devastating genetic neuromuscular disorder that affects motor neurons, leading to progressive muscle weakness and atrophy.
The CHMP’s recommendation is underpinned by the positive outcomes of the Phase III STEER study (NCT05089656). This study indicated that Itvisma could significantly enhance motor function in patients over a 52-week period. Novartis highlights that Itvisma, a one-time, gene-targeting replacement therapy for the survival motor neuron 1 (SMN1) gene, has the potential to alleviate the long-term burden of chronic SMA treatment for individuals aged two and older.
The approval of Itvisma in Europe would further solidify Novartis’s position in the SMA therapeutic landscape, which is currently dominated by its own blockbuster gene therapy, Zolgensma (onasemnogene abeparvovec). If authorized, Itvisma would also represent the first gene replacement therapy for SMA to receive European regulatory approval, offering a potentially new paradigm of care alongside existing treatments such as Zolgensma, Roche’s Evrysdi (risdiplam), and Biogen’s Spinraza (nusinersen).
The SMA market is highly competitive and has seen significant innovation in recent years. Roche’s Evrysdi, a first-in-class non-invasive treatment, has emerged as a leading therapy, becoming the best-selling drug for SMA in 2025. Evrysdi, available in both liquid and pill formulations, received European regulatory approval in June 2025, making it the first non-invasive treatment option for SMA in the region.
The introduction of Itvisma as a gene replacement therapy could offer a distinct advantage by addressing the root genetic cause of SMA. The one-time administration offers the potential for long-lasting benefits, aiming to halt or reverse disease progression. The STEER study’s findings regarding motor function improvement are critical, as preserving motor neuron function is paramount to maintaining quality of life for individuals with SMA.
The CHMP’s endorsement of these three distinct therapies reflects a robust pipeline of innovative treatments reaching advanced stages of regulatory review across Europe. Each drug addresses a critical unmet medical need, and their potential approval could significantly impact patient care and outcomes in their respective disease areas. The regulatory decisions from the EMA, expected in the coming months, will be closely watched by patients, healthcare providers, and the pharmaceutical industry alike. The positive opinions issued by the CHMP serve as a strong indicator of the scientific merit and potential clinical value of these novel therapeutic agents.
Leave a Reply